Dan is Chief Financial Officer at Tevard Biosciences. Since joining the company in 2021, he has played a critical role in shaping financial and operational strategy—first as Vice President of Finance and now as CFO—during a pivotal period of advancement for the company’s tRNA-based gene therapy platform.
Dan brings more than 20 years of progressive leadership experience in pre-commercial and commercial-stage life science companies. Prior to Tevard he held senior finance roles at Spero Therapeutics and AMAG Pharmaceuticals, where he led financial due diligence and integration of a $400 million acquisition and advised the executive team on revenue strategy, financial planning, pricing and contracting governance, and investor communications.
Earlier in his career, Dan held roles at Ironwood Pharmaceuticals and Genzyme Corporation, establishing and managing commercial planning, business intelligence, and financial operations at US and European sites.
Dan holds an MBA from the Massachusetts Institute of Technology (MIT) and earned his undergraduate degree from Northeastern University. He also serves on the Board of the National PKU Alliance.